From Yahoo Finance: 2025-06-13 21:30:00

Johnson & Johnson (NYSE: JNJ) is recommended for retirement portfolios due to its stability and strong performance in 2025, with a dividend yield of 3.4%. UBS global equity strategist Andrew Garthwaite’s team also sees JNJ as a top cyclical pick. Goldman Sachs recently raised its price target on JNJ from $172 to $176, citing its strong balance sheet and revenue growth potential from innovative medicines. JNJ has a strong pipeline with revenue opportunities in various treatments. While JNJ is a strong investment, some AI stocks may offer greater upside potential.



Read more at Yahoo Finance: UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times